Academic Highlights: A Roadmap to Key Pharmacologic Principles in Using Antipsychotics in the Treatment of Bipolar Disorder
J Clin Psychiatry 2008;69(7):1176-1183
© Copyright 2014 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Because this piece has no abstract, we have provided for your benefit the first 3 sentences of the full text.
On the basis of the National Comorbidity Survey Replication (NCS-R), it is estimated that bipolar I and II disorders may affect nearly 3% of the population (i.e., 5.7 million Americans), with the prevalence of subthreshold but still impairing bipolar presentations estimated to be even higher. Bipolar disorder is associated with significant functional impairment and elevated health care costs. Although unipolar depression appears to be over 6 times as prevalent as bipolar disorder, NCS-R data found that the costs of bipolar disorder to the U.S. workplace, estimated at $14.1 billion annually, were almost half the cost of lost productivity associated with unipolar depression.